hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06367738 id: 2024-11-14799 briefTitle: Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults overallStatus: NOT_YET_RECRUITING date: 2025-04-01 date: 2026-12-30 date: 2027-12-30 date: 2024-04-16 date: 2024-04-16 name: University of California, Berkeley class: OTHER briefSummary: We will use cognitive exams, perceptual tasks, brain imaging, peripheral psychophysiology, and surveys to investigate the persisting effects of psilocybin on cognition, predictive coding, and affect in healthy older adults. We will measure changes in these measures by comparing baseline to one-week and one-month post-treatment. Participants will be randomly assigned to receive a dose of psilocybin in a range from microdose to moderate-to-high dose. Dose response will be assessed. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity. We will assess whether changes in these brain measures underlie observed changes in cognition, predictive coding and affect. conditions: Aging studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Psilocybin measure: MRI measurements of brain structure measure: Amplitude and pattern of fMRI cortical responses measure: Peripheral psychophysiology measure: Perceptual measurements measure: Cognitive measurements sex: ALL minimumAge: 60 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06367725 id: 1-10-72-122-23 briefTitle: Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density overallStatus: RECRUITING date: 2024-04-11 date: 2027-12-30 date: 2030-12-30 date: 2024-04-16 date: 2024-04-16 name: University of Aarhus class: OTHER briefSummary: The goal of this observational study is to learn about, the systemic exposure to dexamethason in childhood acute lymphatic leukemia (ALL). The main questions it aims to answer are:
* Visit the clinic four times for a DXA scans to measure bone density and vertebral fracture assessment: within three weeks of starting treatment, six months after starting treatment, one month after finishing treatment, and one year after finishing treatment. Biomarkers related to bone health will also be collected on these days. Additionally, participants will fill out questionnaires to track their daily physical activity levels. conditions: Acute Lymphoblastic Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Area Under the Plasma Concentration Curve (AUC) of Dexamethasone measure: Mineral bone density by DXA-scan measure: Vertebral fracture assessment (VFA) by DXA-scan measure: Dexamethasone in cerebrospinal fluid measure: Physical activity questionnaire measure: Biomarkers of bone metabolism sex: ALL minimumAge: 1 Year maximumAge: 17 Years stdAges: CHILD facility: Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet status: NOT_YET_RECRUITING city: Copenhagen state: København Ø zip: 2100 country: Denmark name: Peter EL Pontoppidan, phd role: CONTACT email: peter.erik.lotko.pontoppidan@regionh.dk lat: 55.67594 lon: 12.56553 facility: Department of Paediatrics and Adolescent Medicine, Odense University Hospital status: NOT_YET_RECRUITING city: Odense state: Odense C zip: 5000 country: Denmark name: Peder S Wehner, phd role: CONTACT email: Peder.Skov.Wehner@rsyd.dk lat: 55.39594 lon: 10.38831 facility: Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital status: NOT_YET_RECRUITING city: Aalborg zip: 9000 country: Denmark name: Marianne Olsen, phd role: CONTACT email: marianne.olsen@rn.dk lat: 57.048 lon: 9.9187 facility: Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital status: RECRUITING city: Aarhus N zip: 8200 country: Denmark name: Karen S Jensen, phd role: CONTACT email: kascje@rm.dk name: Birgitte K Albertsen, Professor role: CONTACT lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06367712 id: Ahmed Kassab briefTitle: Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol overallStatus: COMPLETED date: 2022-11-10 date: 2023-11-01 date: 2023-11-10 date: 2024-04-16 date: 2024-04-16 name: Egymedicalpedia class: INDUSTRY briefSummary: Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor.
Letrozole blocks estrogen synthesis by directly affecting the hypothalamic-pituitary-ovarian axis, subsequently, increases gonadotropins which increase pregnancy rates. Possible positive outcomes of aromatase inhibitors over selective estrogen-receptor modulators include a more physiologic hormonal stimulation of the endometrium which increases receptivity, a lower multiple-pregnancy through single follicle growth, a lesser side-effect especially vasomotor and mood symptoms, and more prompt clearance from blood, hence, reducing the probabilities of periconceptional exposure conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 132 type: ACTUAL name: Letrozole tablets measure: Pregnancy test sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Ahmed Maher Teaching Hospital city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06367699 id: H-44821 briefTitle: Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV) Clinical Trial overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-09 date: 2027-12 date: 2024-04-16 date: 2024-04-16 name: Tufts Medical Center class: OTHER name: Boston Medical Center name: Northeastern University briefSummary: The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and adolescent ECA components on these factors. conditions: Human Papilloma Virus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 1750 type: ESTIMATED name: Usual Care name: ECA-HPV App with Clinic Notification and Adolescent Functions Disabled name: ECA-HPV App with Clinic Notification Function Enabled name: ECA-HPV App with Adolescent Function Enabled name: ECA-HPV App with Clinic Notification and Adolescent Functions Enabled measure: HPV vaccination series completion comparing the control group to the intervention groups measure: HPV vaccination series completion comparing the intervention groups measure: HPV Knowledge measure: HPV Attitudes measure: General Vaccine Attitudes measure: ECA-HPV App Satisfaction measure: Clinic Notification Feature Satisfaction sex: ALL minimumAge: 9 Years maximumAge: 12 Years stdAges: CHILD facility: Boston Medical Center city: Boston state: Massachusetts zip: 02118 country: United States name: Lori Henault, MPH role: CONTACT phone: 617-414-6935 email: lori.henault@bmc.org name: Rebecca Perkins, MD, MSc role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06367673 id: QH-ZYDC-01 briefTitle: Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia overallStatus: RECRUITING date: 2024-04-30 date: 2026-03-31 date: 2026-08-31 date: 2024-04-16 date: 2024-04-18 name: Zhejiang University class: OTHER name: Hangzhou Qihanjiyin Biotech Co.,Ltd. briefSummary: This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML conditions: AML, Adult studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: iPSC-NK cells measure: Incidence of Treatment-Emergent Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the First Affiliated Hospital, School of Medicine, Zhejiang University status: RECRUITING city: Hangzhou state: Zhejiang zip: 321000 country: China name: Yongxian Hu role: CONTACT email: huyongxian2000@aliyun.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06367660 id: 98-2024 briefTitle: Comparison Between Hyperbaric Bupivacaine With Fentanyl vs. Hyperbaric Bupivacaine With Dexmedetomidine in Reducing Visceral Pain During Cesarean Delivery Under Spinal Anaesthesia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-09 date: 2024-04-16 date: 2024-04-24 name: Tribhuvan University Teaching Hospital, Institute Of Medicine. class: OTHER briefSummary: In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale conditions: Visceral Pain studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Research method: Quantitative Type of study: Randomized, interventional, comparative study primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 168 type: ESTIMATED name: Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine measure: Primary outcome measure: Secondary Outcome sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06367647 id: zhujiangjy-20240229 briefTitle: Investigation on the Detection Rate of Pathogenic Viruses in Feces of Parenteral Infected Individuals overallStatus: RECRUITING date: 2024-04-15 date: 2025-10-31 date: 2025-12-31 date: 2024-04-16 date: 2024-04-22 name: Zhujiang Hospital class: OTHER briefSummary: This project is a cross-sectional study. Investigators plan to search and collect 1600 publicly published fecal metagenomic and metatranscriptome data through the Pubmed database, by summarizing and analyzing them to construct an enterovirus database. 200 apparently healthy individuals are planned to be enrolled. At the time of enrollment, fecal specimens of participants will be collected, and their demographic characteristics, disease and medication history, gastrointestinal status, dietary habits, lifestyle habits, and mental health information will be recorded. Another 200 specimens will be collected from patients with parenteral virus infection. The demographic characteristics and pathogen test results of the parenteral virus infected patients will be reviewed and recorded. By virus metagenomic sequencing on fecal specimens, investigators will identify which viruses can be detected in the intestinal tract of apparently healthy people, and to explore whether parenteral infection viruses can be detected in feces. conditions: Virus Infections studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 2000 type: ESTIMATED measure: virus infection checklist measure: general information of apparently healthy individuals by questionnaire measure: Self-Rating Anxiety Scale SAS measure: Self-rating depression scale SDS measure: Pittsburgh sleep quality index PSQI measure: demographic characteristics case information of parenteral virus infected patients sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhujiang hospital of southern medical university status: RECRUITING city: Guangzhou state: Guangdong zip: 510280 country: China name: Yumei Liu, master role: CONTACT phone: +8618810795365 email: liuyumei1007@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06367634 id: TEO-TSUL-2301 briefTitle: TEOSYAL® PureSense ULTRA DEEP Versus Restylane® Lidocaine for the Correction of Moderate to Severe Nasolabial Folds in Chinese Adults overallStatus: RECRUITING date: 2024-01-19 date: 2025-01 date: 2026-02 date: 2024-04-16 date: 2024-04-16 name: Teoxane SA class: INDUSTRY briefSummary: This is a prospective, multi-center, randomized, controlled, subject- and evaluator-blinded clinical investigation to demonstrate non-inferiority of TEOSYAL® PureSense ULTRA DEEP compared to Restylane® Lidocaine for the correction of moderate to severe NLF in Chinese adults.
All subjects will return to the site at 4, 12, 24, 36, and 52 weeks after the last treatment for effectiveness and safety assessment. All subjects will receive a safety phone call 7 days after the initial treatment at baseline, and after the touch-up treatment, if applicable. conditions: Nasolabial Folds studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Blinded-Live evaluator whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 390 type: ESTIMATED name: injection in NLF measure: WSRS grading sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guangdong Second Provincial General Hospital status: RECRUITING city: Guangzhou country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06367621 id: CLS-015C briefTitle: Retrospective Study of iStatis Syphilis Ab Test (POC) overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-15 date: 2024-04-15 date: 2024-04-15 date: 2024-04-16 date: 2024-04-16 name: bioLytical Laboratories class: INDUSTRY briefSummary: The purpose of this retrospective clinical trial is to establish the clinical performance of the iStatis Syphilis AbTest. The data will be used to demonstrate the product is safe and effective for its intended use. The data obtained will be used in the application for CE certification under In Vitro Diagnostic Medical Device Regulation (IVDR) and World Health Organization (WHO) prequalification. conditions: Syphilis conditions: Syphilis Infection studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 1500 type: ACTUAL name: iStatis Syphilis Antibody Test measure: Sensitivity and specificity of the iStatis Syphilis Ab Test sex: ALL minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Epicentre Health Research city: Hillcrest state: KwaZulu Natal zip: 3650 country: South Africa hasResults: False
nctId: NCT06367608 id: HP-00104695 briefTitle: MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD) acronym: FUS Dystonia overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-06 date: 2028-06 date: 2024-04-16 date: 2024-04-25 name: University of Maryland, Baltimore class: OTHER name: Focused Ultrasound Foundation name: InSightec briefSummary: The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating task specific focal hand dystonias (TSFD). TSFD is a type of dystonia that affects hand movements during specific tasks such as writing, playing instruments or typing, often causing involuntarily movements or cramping. conditions: Task-Specific Focal Dystonia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 10 type: ESTIMATED name: ExAblate Transcranial treatment measure: Incidence of Treatment related adverse events measure: Change in dystonia intensity measure: Change in patient's perception of quality of life measure: Change in patient's perception of the effect of the procedure sex: ALL minimumAge: 21 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Maryland Medical Center city: Baltimore state: Maryland zip: 21201 country: United States name: Kaitlyn Henry, MS role: CONTACT phone: 410-328-0939 email: khenry@som.umaryland.edu name: Rayne Noyes, BS role: CONTACT email: anoyes@som.umaryland.edu lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06367595 id: Intrathecal MgSO4 briefTitle: Effect of Intrathecal Magnesium Sulfate Versus Intravenous Magnesium Sulfate on Postoperative Pain After Abdominal Hysterectomy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-10 date: 2026-11 date: 2024-04-16 date: 2024-04-16 name: Assiut University class: OTHER briefSummary: The present study aims to compare the effect of adding IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine in total abdominal hysterectomy regarding the duration of postoperative analgesia, hemodynamic stability, and complications. conditions: Abdominal Hysterectomy studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 90 type: ESTIMATED name: Magnesium sulfate measure: effect on postoperative pain after abdominal hysterectomy using visual analog score measure: sedation by Ramsay sedation scale measure: time of the first opioid request measure: Mean arterial blood pressures (MAP) measure: Heart rate (HR) sex: FEMALE minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06367582 id: CV01-TK-SPINE briefTitle: SPINE BONE CEMENTS OUTCOMES overallStatus: RECRUITING date: 2019-09-04 date: 2029-09-04 date: 2039-09-30 date: 2024-04-16 date: 2024-04-16 name: Teknimed class: INDUSTRY briefSummary: A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and performance of all TEKNIMED Spine range of products: SPINEFIX, HIGH V+, OPACITY+ and F20 bone cements and mixing and injection systems, and all their private labels.
nctId: NCT06367569 id: 2012//375 briefTitle: Evaluation of MRI of the Pineal Gland in Retinoblastoma acronym: TRbFU overallStatus: COMPLETED date: 2012-10-01 date: 2023-09-01 date: 2023-09-01 date: 2024-04-16 date: 2024-04-16 name: Amsterdam UMC, location VUmc class: OTHER briefSummary: Rationale: Currently baseline brain MRI (magnetic resonance imaging) with extended follow-up of pineal cysts is systematically performed in all new retinoblastoma (Rb) patients, because children with hereditary retinoblastoma have an increased risk of primitive neuroectodermal tumors (PNET) that are histopathologically identical to the retinal tumors (1). The prevalence of developing a PNET in combination with unilateral or bilateral hereditary Rb is 5-15% (2). Treatment is difficult and the prognosis is poor as only few survivors are reported. Only patients with small asymptomatic PNETs (\<15 mm) are potentially curable.
Main study parameters/endpoints: The primary endpoint of the study is pineoblastoma or supra- / parasellar PNET on MRI (index test). Because a gold standard will not be available, tumor cells in cerebrospinal fluid, histopathological confirmation, clinical disease progression during follow-up, and/or follow-up MRI diagnostics will be used as a composite reference standard in case of a positive index test and clinical diagnosis of pineoblastoma or supra- / parasellar PNET within one year of the last MRI will be used as a composite reference standard in case of a negative index test. conditions: Retinoblastoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 607 type: ACTUAL name: Screening for trilateral retinoblastoma with MRI measure: Diagnostic accuracy of the screening measure: Survival analysis of trilateral retinoblastoma patients sex: ALL minimumAge: 0 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: VU University Medical Center city: Amsterdam state: Noord-Holland zip: 1081 HV country: Netherlands lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06367556 id: 4542 briefTitle: Emotion and Symptom-Focused Engagement (EASE) for Caregivers acronym: EASE overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2027-10-01 date: 2028-10-01 date: 2024-04-16 date: 2024-04-16 name: University Health Network, Toronto class: OTHER name: The Hospital for Sick Children name: Canadian Institutes of Health Research (CIHR) briefSummary: The goal of this two-site phase III randomized controlled trial is to evaluate the effectiveness of a novel psychotherapeutic intervention called Emotion and Symptom-focused Engagement (EASE) in parents caring for a child or adolescent with cancer. The main question it aims to answer is:
To do so, researchers will compare parents receiving EASE to usual care. Participants in both groups will complete questionnaires package at enrolment, and 4, 8, and 12 weeks, and 6 months after enrolment. They will also be invited to participate in optional qualitative interviews to better understand their experience. conditions: Trauma and Stressor Related Disorders conditions: Pediatric Cancer conditions: Caregiver Burden studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Quantitative outcome assessors and data analysts will be blinded to participant treatment group. Blinding is not possible for trial participants, intervention providers, or pediatric oncology teams, as assignment cannot be hidden from these individuals. whoMasked: OUTCOMES_ASSESSOR count: 306 type: ESTIMATED name: EASE measure: Posttraumatic Stress Disorder Checklist for DSM-5 [PCL-5] measure: SF-36v2 Health Survey measure: Patient Health Questionnaire [PHQ-9] measure: Caregiving Health Engagement Scale [CHE-s] measure: Family Adaptability and Cohesion Evaluation Scales III [FACES-III] measure: Clinical Evaluation Questionnaire [CEQ] measure: Family Satisfaction with End-of-Life Care Tool, 10-item version [FAMCARE-10] measure: Traditional Masculinity-Femininity Scale [TMF] measure: Caregiver Reaction Assessment Scale [CRA] measure: ENRICHD Social Support Instrument [ESSI] measure: Experiences in Close Relationships Scale [ECR-16] measure: Hope of Improvement subscale of the Therapy Expectation and Evaluation Scale [PATHEVH] sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False